This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation

Cost-effectiveness analysis
Study objective
To assess the costs and benefits associated with dexmedetomidine for the sedation of adult medical and surgical intensive care unit (ICU) patients requiring mechanical ventilation for more than 24 hours.
Interventions
The intervention was dexmedetomidine (0.15μg/kg/mL). The comparator was lorazepam (1mg/mL). Each drug was titrated by the bedside nurse to a maximum of 10mL/hour (1.5μg/kg per hour for dexmedetomidine or 10mg/hour for lorazepam) to achieve the sedation goal set by the patient's medical team using the Richmond Agitation Sedation Scale (RASS). The administered drug was infused as needed until extubation or 120 hours was reached. Beyond 120 hours patients were treated with lorazepam or midazolam according to each intensive care unit's usual protocol.
Location/setting
USA/in-patient
Methods
Analytical approach:
An economic evaluation based on a single trial. The study had a 12 month time horizon. The authors did not state the perspective but appeared adopt a health service perspective.
Effectiveness data:
Effectiveness data were based on a double-blind randomised controlled trial of 106 adult mechanically ventilated medical and surgical intensive care unit patients conducted between August 2004 and April 2006 at two tertiary care centres in USA (Vanderbilt University Medical Center and Washington Hospital Center). Participants were randomised to be sedated with either dexmedetomidine (52 patients) or lorazepam (51 patients) for up to 120 hours. Patients were followed for up to 12 months. Data were analysed using an intention-to-treat approach.
The primary measures of effectiveness were number of delirium-free or coma-free days and the percentage of days spent within the target level of sedation. Both measures were obtained directly for observational data from the trial. Delirium was measured using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Patients were monitored twice daily for delirium for 12 days or until hospital discharge. Patients were categorised as having delirium if they had a RSS score of -3 or greater and a positive CAM-ICU. Coma was defined as a RASS score of -4 or -5. Sedation level was measured using the RASS: a patient was defined as achieving the target level of sedation if they were within one RASS point of the sedation goal. Target sedation levels were defined both by the nurse and physician
Results
From study days one to 12, patients treated with dexmedetomidine experienced a median of seven days with and interquartile range (IQR) of one to 10 delirium-free and coma-free days compared with three days (IQR one to six) for lorazepam patients (p=0.01). Eighty-seven per cent of patients treated with dexmedetomidine experienced delirium or coma at some point in the 12-day assessment period compared with 98% in the lorazepam group (p=0.03).
Patients treated with dexmedetomidine were at or within one RASS point of the nurse's stated sedation goal for a median of 80% (IQR 58% to 100%) of the time while on study drugs compared to 67% (IQR 48% to 83%) for those treated with Lorazepam (p=0.04). For the physician's goal, the associated results were 67% (IQR 50% to 85%) for dexmedetomidine patients and 55% (IQR 8% to 67%) for lorazepam patients (p=0.008).
The 28-day mortality in the dexmedetomidine group was 17% versus 27% in the lorazepam group (p=0.18). The 12-month time to death was 363 in the dexmedetomidine group versus 188 days in the lorazepam group (p=0.48).
Median drug costs were $4,675 in the dexmedetomidine group and $2,335 in the lorazepam group. In the dexmedetomidine group, median costs were $27,460 (IQR $15, 710 to $46, 430) for pharmacy, $3,530 (IQR $2,170 to $6,940) for respiratory care, $61,400 (IQR $37,300 to $108,200) for intensive care unit costs and $101,400 for hospital costs. In the Lorazepam group, median costs were $20,660 (IQR $9,840 to $42,270) for pharmacy, $2,920 (IQR $2,070 to $5,830) for respiratory care, $59,500 (IQR $35,900 to $83,000) for intensive care unit costs and $78,900 (IQR $44,000 to $124,600) for hospital costs. All p values were non-significant for the care costs. methodology and participant characteristics were reported clearly. Given that the effectiveness outcomes were derived from a relatively small sample of patients from two tertiary American centres, it was likely that the effectiveness results would generalise only to similar centres treating patients with comparable demographics.
Benefit measures were appropriate for this study and were described appropriately but were specific to the study setting and population. A more generic measure such as quality-adjusted life-years (days) may have increased the generalisability of the study.
Costs:
The study perspective was not stated clearly; it appeared that the appropriate cost categories were included for a health care perspective. Costs were reported clearly but the specific items included in care costs were not reported. In particular it was unclear what costs were included in hospital costs. The methods used to derive costs appeared appropriate. Costs were derived directly from a single USA tertiary medical centre so it was likely that the cost results would generalise only to other USA tertiary centres with a similar demographic. The costs appeared to be adjusted appropriately for inflation and appropriately were not discounted due to the short time horizon.
Analysis and results:
Effectiveness and cost outcomes were presented only in a disaggregated format: there was no form of incremental analysis to assess the cost-effectiveness of dexmedetomidine so it was difficult to interpret the results and reach a conclusion about cost-effectiveness. There was no assessment of uncertainty and this precluded conclusions about the robustness of the results; this was a key limitation of the study.
